Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
  • A61K31/7024—Esters of saccharides
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K39/00—Medicinal preparations containing antigens or antibodies
  • A61K39/12—Viral antigens
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
  • C12N2740/00—Reverse transcribing RNA viruses
  • C12N2740/00011—Details
  • C12N2740/10011—Retroviridae
  • C12N2740/16011—Human Immunodeficiency Virus, HIV
  • C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
  • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
  • C12N2760/00011—Details
  • C12N2760/14011—Filoviridae

Definitions

• the present invention relates to the use of at least one mono-, di- or tri-sulphated pentose or hexose amine in accordance with the structure formula (I), and salts thereof, as physiologically active substances or active substances in pharmaceuticals having antiviral, antibacterial and antimycotic effect.
• the invention also relates to pharmaceutical compositions containing sulphated pentose or hexose amines in accordance with the structure formula (I), or mixtures thereof.
• R 1 is hydrogen, -C 6 -alkyl, benzyl, amino acid, such as serine or asparagine, polypeptide or nucleotide, such as adenosine, guanosine, thymidine, cytidine or uridine diphosphate;
• R2 is hydrogen, Ci-C ⁇ -alkyl, acetyl or C 2 -C 2 -acyl, amino acyl or sulphonyl;
• X3 is OH or S0 - X4 is OH or SO 4 -
• X5 is OH or SOf ,
• X6 is OH or SO 4
• Y + Y 2 - * is H, Na, K, Ca, Zn, Mg, Li, Ba, Mn, Hg, Ag or Au.
• HIV Human Immunodeficiency Virus
• glycolipids which are the main components in plasma membrane and have an important function in cell recognition, e.g. certain of the blood group substances, have shown that these can be used as binding points for certain virus and bacteria toxins. These studies gave rise to the investigation of various forms of sulphated hexoses and pentoses.
• a typical sulphated disaccharide is ⁇ - ⁇ UA- [1.3] - GalNAc-4S, which constituted the subject of the extremely extensive investigations performed in connection with the invention. In virological tests the compound exhibited antiviral activity but also had extremely high cell toxic effect.
• the present invention relates to the use of sulphated pentose amines and hexose amines in pharmaceuticals for the treatment of infections, particularly virus infections, of the retrovirus or filovirus family, for instance, represented by Human Immimodeficiency Virus (HIV), Ebola Zaire, Ebola Sudan, Ebola Reston and Marburg virus.
• HIV Human Immimodeficiency Virus
• Ebola Zaire Ebola Sudan
• Ebola Reston and Marburg virus for instance, represented by Human Immimodeficiency Virus (HIV), Ebola Zaire, Ebola Sudan, Ebola Reston and Marburg virus.
• the present invention therefore constitutes an essential contribution to the existing therapy arsenal for treating resistant strains of bacteria and fungi.
• the present invention relates to the use of sulphated pentose and hexose amines in accordance with the structure formula (I), as antiviral, antibacterial and antimycotic compositions for treating diseases caused by these micro-organisms.
• the invention also relates to a pharmaceutical composition characterized by a percentage of a compound in accordance with formula (I) or its pharmacologically compatible acid addition salt, as active substance and also ordinary carrier and thinning agents.
• the compounds used according to the invention can be administered in the normal way orally, parenterally, intravenously or intramuscularly or in the form of ointments or as a vaccine.
• the active substances according to the invention can be used individually or combined with each other, thus offering greater treatment opportunity against mutations or the occurrence o f resistance.
• Dosing is adjusted to the patient's weight, general condition, age and method of administering.
• R 1 is hydrogen, - -alkyl, benzyl, amino acid, such as serine or asparagine, polypeptide or nucleotide, such as adenosine, guanosine, thymidine, cytidine or uridine diphosphate;
• R 2 is hydrogen, C ⁇ -C 6 -alkyl, acetyl or C2-C 24 -acyl, amino acyl or sulphonyl;
• X3 is OH or S0 4 -;
• X 4 is OH or SO4-;
• X 6 is OH or SO 4 -;
• Y + , Y 2+ is H, Na, K, Ca, Zn, Mg, Li, Ba, Mn, Hg, Ag or Au.
• the most preferred compound for use as pharmaceutical according to the invention has the structure formula (III):
• the substance in accordance with formula (I) is used in pharmaceuticals intended as antiviral compositions, preferably as a cure for HIV infections and AIDS.
• the compound in accordance with formula (I) is used in pharmaceuticals intended to combat AIDS-related cancer illnesses such as Karposi's sarcoma and lymphatic gland cancer in which viruses play a part.
• Another preferred embodiment of the invention is the use of the compound in accordance with formula (I) in pharmaceuticals intended as antibacterial preparations, primarily as cures against bacteria which have become resistant to antibiotics.
• Another preferred embodiment is the use of the compound in accordance with formula (I) against fungal diseases.
• Another preferred embodiment of the invention is the use of the compound in accordance with formula (I) for combating parodontal diseases in which viruses, bacteria or fungi play a part.
• Another preferred embodiment of the invention is the use of active substances in accordance with formula (I) for the production of vaccine serum, as complex together with viruses /bacteria that have been inactivated, or as complex in the form of serum that is activated by the composition according to the invention.
• Another preferred embodiment of the invention is the use of 4-0- sulpho-N-acetyl-D-galactose amine (LenticinTM) as active substance in pharmaceuticals against HIV and HIV-related diseases. (LenticinTM will be included as active substance in the pharmaceutical LentivirTM).
• Another preferred embodiment of the invention is the use of 4-0- sulpho-N-acetyl-D-glucose amine (FilocinTM) as active substance in pharmaceuticals against various forms of Ebola diseases. (FilocinTM will be included as active substance in the pharmaceutical FilovirTM).
• the preferred amino-sugars are mono-, di- or tri- sulphated amino-D-glucose or amino-D-galactose, preferably mono-, di- or tri-sulphated amino-D-galactose.
• compositions according to the invention comprising mono-, di- or tri-sulphated pentose or hexose amine derivatives as active substance, include various forms of carrier materials in the form of solutions, powder or ointment which shall be physiologically compatible and non-irritant.
• carrier materials include water, aliphatic alcohols with a chain length within the interval C-20 to C-26, starch or vegetable oils.
• a preferred pharmaceutical composition includes a carrier which preferably constitutes water or aliphatic alcohols with a chain length within the interval C-20 to C-26.
• Another preferred pharmaceutical composition includes a carrier which preferably constitutes starch or vegetable oils.

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Public Health (AREA)
• Animal Behavior & Ethology (AREA)
• Veterinary Medicine (AREA)
• Medicinal Chemistry (AREA)
• Chemical & Material Sciences (AREA)
• General Health & Medical Sciences (AREA)
• Pharmacology & Pharmacy (AREA)
• Epidemiology (AREA)
• Microbiology (AREA)
• Mycology (AREA)
• Virology (AREA)
• Immunology (AREA)
• Molecular Biology (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Priority Applications (1)

Applications Claiming Priority (2)

Publications (1)

Family

ID=20398704

Family Applications (1)

Country Status (3)

Citations (3)

• 1995
  • 1995-06-21 SE SE9502265A patent/SE9502265D0/sv unknown
• 1996
  • 1996-06-20 AU AU62479/96A patent/AU6247996A/en not_active Withdrawn
  • 1996-06-20 WO PCT/SE1996/000825 patent/WO1997000685A1/en active Application Filing

Patent Citations (3)

Non-Patent Citations (2)

Also Published As

Similar Documents

Legal Events